CDMO Sterile Fill-Finish 506e Outsourcing Contract Manufacturer for Once-a-Week Insulin Icodec 700u/mL

Insulin icodec is an ultra-long-acting basal insulin analog engineered with fatty acid side chains that bind reversibly to albumin, creating a large subcutaneous depot. This albumin-binding mechanism extends the half-life to approximately 196 hours (8.2 days), enabling once-weekly subcutaneous dosing. Icodec activates the insulin receptor to suppress hepatic glucose production, stimulate peripheral glucose uptake in muscle and adipose tissue, and inhibit lipolysis — providing stable 24/7 basal glycemic coverage across the full week.

Initiated at 70 units (0.1 mL of 700 u/mL) subcutaneously once weekly. Dose is titrated in increments of 10–20 units based on fasting glucose targets. Each 1 mL cartridge contains 700 units. Standard pen delivers doses in 2-unit increments. Administered on the same day each week, at any time of day, with or without meals.

Insulin degludec is an ultra-long-acting basal insulin analog with a unique multi-hexamer chain-forming mechanism. Upon subcutaneous injection, degludec self-assembles into soluble multi-hexamers that slowly dissociate into monomers for absorption, creating a depot with a half-life exceeding 25 hours and a duration of action up to 42 hours. This flat, peakless pharmacokinetic profile minimizes nocturnal hypoglycemia risk while providing consistent basal insulin coverage. Degludec activates the insulin receptor to suppress hepatic glucose output and promote peripheral glucose utilization.

Starting dose for insulin-naïve type 2 diabetes: 10 units (0.1 mL of 100 u/mL) once daily subcutaneously. For type 1 diabetes, one-third of total daily insulin requirement. Available as 100 u/mL (FlexTouch pen, 3 mL cartridge = 300 units) and 200 u/mL (FlexTouch pen, 3 mL cartridge = 600 units). Titrate every 3–4 days targeting fasting glucose. Flexible dosing window — can be administered at any time of day.

Insulin detemir is a long-acting basal insulin analog with a C14 fatty acid chain attached to lysine B29, enabling reversible albumin binding in the bloodstream. This dual mechanism — albumin binding plus self-association at the injection site — prolongs absorption and extends the duration of action to approximately 24 hours. Detemir provides a relatively flat, predictable pharmacokinetic profile with lower intra-individual variability compared to NPH insulin. It activates insulin receptors to suppress hepatic glucose production and stimulate peripheral glucose uptake.

Insulin-naïve type 2 diabetes: 10 units (0.1 mL) once daily at bedtime, or 0.1–0.2 units/kg once daily. Type 1 diabetes: approximately 50% of total daily insulin requirement as basal. Available as 100 u/mL in 3 mL FlexPen cartridges (300 units per pen). Dose titrated every 3 days. May be administered once or twice daily depending on glycemic response.

Insulin glargine is a long-acting basal insulin analog engineered with two arginine residues added to the C-terminus of the B-chain and a glycine substitution at position A21. These modifications shift the isoelectric point to pH 6.7, causing microprecipitate formation at physiological pH upon subcutaneous injection. This depot slowly dissolves, releasing insulin glargine monomers at a consistent, peakless rate over 24 hours. Glargine activates insulin receptors to suppress hepatic glucose production and promote glucose uptake in peripheral tissues.

100 u/mL formulation: type 2 diabetes starting dose 0.2 units/kg or 10 units once daily subcutaneously. 300 u/mL (Toujeo): starting dose 0.2 units/kg once daily — delivers one-third the injection volume of 100 u/mL. Available in 3 mL SoloStar pen (300 units at 100 u/mL) and 1.5 mL Max SoloStar pen (450 units at 300 u/mL). Titrate every 3–7 days. Administer at the same time each day.

Insulin aspart is a rapid-acting mealtime insulin analog with a single amino acid substitution — proline replaced by aspartic acid at position B28 — that reduces self-association and accelerates subcutaneous absorption. Onset of action occurs within 10–20 minutes of injection, peak effect at 1–3 hours, and duration of 3–5 hours. Aspart activates insulin receptors to rapidly suppress postprandial hepatic glucose production, stimulate glucose uptake in skeletal muscle and adipose tissue, and inhibit glucagon secretion — closely mimicking physiological first-phase insulin secretion.

Administered subcutaneously 5–10 minutes before the start of a meal, or within 20 minutes after beginning a meal. Typical starting dose: 4 units per meal or 10% of total daily insulin dose per meal. Available as 100 u/mL in 3 mL FlexPen cartridges (300 units per pen). Dose individualized based on carbohydrate intake and pre-meal glucose. Used in combination with a basal insulin in basal-bolus regimens.